Pharmacological characterization of T-2328, 2-fluoro-4′-methoxy- 3′-[[[(2S,3S)-2-phenyl-3-piperidinyl]amino]methyl]-[1,1′-biphenyl] -4-carbonitrile dihydrochloride, as a brain-penetrating antagonist of tachykinin NK1 receptor

Journal of Pharmacological Sciences

Volumn 106, Issue 1, 2008, Pages 121-127

  Watanabe, Yumi ^a   Asai, Hidetoshi ^a   Ishii, Taketoshi ^a   Kiuchi, Satoko ^a   Okamoto, Masahito ^a   Taniguchi, Hiroyuki ^a   Nagasaki, Masaaki ^a   Saito, Akira ^a  

^a MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

Author keywords

Anti emetic; Brain penetrative; Cisplatin; Delayed emesis; NK1 antagonist

Indexed keywords

2 FLUORO 4' METHOXY 3' [[(2 PHENYL 3 PIPERIDINYL)AMINO]METHYL] [1,1' BIPHENYL] 4 CARBONITRILE; 5 AMINOVALERYLSUBSTANCE P [7-11][9 PROLINE 10 (N METHYLLEUCINE)]; APREPITANT; CISPLATIN; ION CHANNEL; NEUROKININ 1 RECEPTOR ANTAGONIST; NEUROKININ 2 RECEPTOR; NEUROKININ 3 RECEPTOR; SAREDUTANT; T 2328; TACHYKININ RECEPTOR ANTAGONIST; TALNETANT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CELL STRAIN IM 9; CHO CELL; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; FEMALE; GERBIL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; RECEPTOR AFFINITY; VOMITING;

EID: 38549151079     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.FP0071400     Document Type: Article

References (23)

1. Otsuka M, Yoshioka K. Neurotransmitter functions of mammalian tachykinins. Physiol Rev. 1993;73:229-308.
2. Severini C, Improta G, Falconieri-Erspamer G, Salvadori S, Erspamer V. The tachykinin peptide family. Pharmacol Rev. 2002;54:285-322.
3. Rigby M, O'Donnell R, Rupniak NM. Species differences in tachykinin receptor distribution: further evidence that the substance P (NK1) receptor predominates in human brain. J Comp Neurol. 2005;490:335-353.
4. Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin - the Aprepitant Protocol 052 Study Group. J Clin Oncol. 2003;21:4112-4119.
5. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Julie Ma G, Eldridge K, Hipple A, et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer. 2003;97:3090-3098.
6. Kramer MS, Cutler N, Feighner J, Shrivastava R, Carman J, Sramek JJ, et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science. 1998;281:1640-1645.
7. Furmark T, Appel L, Michelgard A, Wahlstedt K, Ahs F, Zancan S, et al. Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo. Biol Psychiatry. 2005;58:132-142.
8. Quartara L, Altamura M. Tachykinin receptors antagonists: from research to clinic. Curr Drug Targets. 2006;7:975-992.
9. Hale JJ, Mills SG, MacCoss M, Finke PE, Cascieri MA, Sadowski S, et al. Structural optimization affording 2-(R)-(1-(R)-3,5-bis(trifluoromethyl) phenylethoxy)-3-(S)-(4-fluoro)phenyl-4-(3-oxo-1,2,4-triazol-5-yl) methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist. J Med Chem. 1998;41:4607-4614.
10. Tattersall FD, Rycroft W, Cumberbatch M, Mason G, Tye S, Williamson DJ, et al. The novel NK1 receptor antagonist MK-0869 (L-754,030) and its water soluble phosphoryl prodrug, L-758,298, inhibit acute and delayed cisplatin-induced emesis in ferrets. Neuropharmacology. 2000;39:652-663.
11. Girish C, Manikandan S. Aprepitant: a substance P antagonist for chemotherapy induced nausea and vomiting. Indian J Cancer. 2007;44:25-30.
12. Rudd JA, Jordan CC, Naylor RJ. The action of the NK1 tachykinin receptor antagonist, CP 99,994, in antagonizing the acute and delayed emesis induced by cisplatin in the ferret. Br J Pharmacol. 1996;119:931-936.
13. McLean S, Ganong A, Seymour PA, Bryce DK, Crawford RT, Morrone J, et al. Characterization of CP-122,721; a nonpeptide antagonist of the neurokinin NK1 receptor. J Pharmacol Exp Ther. 1996;277:900-908.
14. Walpole CS, Brown MC, James IF, Campbell EA, McIntyre P, Docherty R, et al. Comparative, general pharmacology of SDZ NKT 343, a novel, selective NK1 receptor antagonist. Br J Pharmacol. 1998;124:83-92.
15. McLean S, Ganong A, Seymour PA, Snider RM, Desai MC, Rosen T, et al. Pharmacology of CP-99,994; a nonpeptide antagonist of the tachykinin neurokinin-1 receptor. J Pharmacol Exp Ther. 1993;267:472-479.
16. Bristow LJ, Young L. Chromodacryorrhea and repetitive hind paw tapping: models of peripheral and central tachykinin NK1 receptor activation in gerbils. Eur J Pharmacol. 1994;253:245-252.
17. Rupniak NM, Williams AR. Differential inhibition of foot tapping and chromodacryorrhoea in gerbils by CNS penetrant and non-penetrant tachykinin NK1 receptor antagonists. Eur J Pharmacol. 1994;265:179-183.
18. Navari RM, Province PS. Emerging drugs for chemotherapy-induced emesis. Expert Opin Emerg Drugs. 2006;11:137-151.
19. Aapro M. Optimising antiemetic therapy: what are the problems and how can they be overcome? Curr Med Res Opin. 2005;21:885-897.
20. Saito R, Takano Y, Kamiya HO. Roles of substance P and NK(1) receptor in the brainstem in the development of emesis. J Pharmacol Sci. 2003;91:87-94.
21. Rupniak NM, Tattersall FD, Williams AR, Rycroft W, Carlson EJ, Cascieri MA, et al. In vitro and in vivo predictors of the antiemetic activity of tachykinin NK1 receptor antagonists. Eur J Pharmacol. 1997;326:201-209.
22. Kraut L, Fauser AA. Anti-emetics for cancer chemotherapy-induced emesis: Potential of alternative delivery systems. Drugs. 2001;61:1553-1562.
23. Meurer LC, Finke PE, Owens KA, Tsou NN, Ball RG, Mills SG, et al. Cyclopentane-based human NK1 antagonists. Part 2: development of potent, orally active, water-soluble derivatives. Bioorg Med Chem Lett. 2006;16:4504-4511.